Author

Sarah Dudley

Observed name: Dudley, Sarah

Institution: Synairgen (United Kingdom)

Observed institutions: Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, Synairgen (United Kingdom)

OpenAlex ID: A5020002494

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

2020 · Phillip D Monk, Richard J Marsden, et al. · The Lancet Respiratory Medicine · 431

The Effect of Inhaled IFN-β on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial

2014 · Ratko Djukanović, Tim Harrison, et al. · American Journal of Respiratory and Critical Care Medicine · 267

Barrier responses of human bronchial epithelial cells to grass pollen exposure

2012 · Cornelia Blume, Emily J. Swindle, et al. · European Respiratory Journal · 71

Susceptibility to influenza virus infection of bronchial biopsies in asthma

2017 · Ben Nicholas, Sarah Dudley, et al. · Journal of Allergy and Clinical Immunology · 18

Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD

2024 · Phillip D. Monk, Jody L. Brookes, et al. · Respiratory Research · 13

375. The Effect of Inhaled Interferon Beta-1a (SNG001) Treatment Compared to Placebo on Lung Antiviral Biomarkers and Viral Clearance in Chronic Obstructive Pulmonary Disease (COPD) Patients With Respiratory Virus Infections

2023 · Phillip D Monk, Jody L Brookes, et al. · Open Forum Infectious Diseases · 2

Susceptibility to influenza virus infection in asthma biopsies and the effect of topical steroids

2015 · Ben Nicholas, Sarah Dudley, et al. · European Respiratory Journal

Works count: 9

Citation count: 812

H-index: 5

I10-index: 5